Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.

Özcan, MuhitLee, Seung TaeMensah, FelixModi, DipenkumarFossa, AlexanderKim, Won SeogPaszkiewicz-Kozik, EwaSevindik, Ömür GökmenLavie, David2024-01-312024-01-312023Özcan, M., Lee, S. T., Mensah, F., Modi, D., Fossa, A., Kim, W. S. ... Lavie, D. (2023). Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 41(16). Chicago, IL, 02-06 June, 2023.0732-183X1527-7755https://hdl.handle.net/20.500.12511/12223[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessDLBCLZilovertamab Vedotin (MK 2140)Relapsed/Refractory (R/R)Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.Conference Object4116Q1001053772003474N/A